RV7.DU Stock Analysis
RV
Attractive
Based on Eyestock quantitative analysis, RV7.DU`s fundamental data and valuation indicate an investment grade of Attractive at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 393 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. The company has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.